Introduction Bacterial infections remain the leading killer worldwide which is worsened by the continuous emergence of antibiotic resistance. In particular, antibiotic resistant Gramnegative bacteria are prevalent and extremely difficult to treat. Therefore, rejuvenating the therapeutic potentials of existing antibiotics represents an attractive novel strategy. Antimicrobial peptides have been of great focus recently. Newly derived synthetic lipopeptides have been shown to exhibit antimicrobial activity against bacteria and fungi.